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February 2016 Abstracts S49Signiﬁcantly reduced expression of immunoprotea-
some components and their regulators was observed to
be associated with epithelial to mesenchymal transition
in 42 NSCLC cell lines using proteomic proﬁling and
microarray analysis. A highly variable immunopro-
teasome expression was also observed among NSCLC
tissues. Immunohistochemistry data revealed loss of
immunoproteasome subunit is signiﬁcantly correlated
with expression of CDH2 and concomitant loss of
CDH1 in NSCLC tumors. Loss of immunoproteasome
subunits was also signiﬁcantly associated with
advanced stage (p¼0.014), recurrence (p¼0.002) and
metastasis (p<0.01) in NSCLC patients. A signiﬁcantly
reduced antigen presentation was observed in
mesenchymal cell lines compared to epithelial cells.
Using mild acid elution, only 50-60 HLA class I bound
peptides were identiﬁed in mesenchymal cell lines
compared to 400-500 peptides in epithelial counter-
parts. IFNg as well as 5-aza-2’-deoxycytidine treat-
ment was able to revive immunoproteasome
expression and hence restored repertoire of HLA class
I bound peptides in deﬁcient mesenchymal cells.
Induced expression of immunoproteasome and hence
HLA class I bound peptides also lead to signiﬁcantly
enhanced CD8þ T cell mediated cytotoxicity (p<0.01)
in mesenchymal cells compared to non-induced con-
trols. Our ﬁndings point towards a mechanism of
immune evasion of cells with a mesenchymal pheno-
type and strategies to overcome their immune evasion
through induction of the immunoproteasome or tar-
geting the limited repertoire of peptides presented in
common by these cell types.
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Several lines of evidence indicated that the anti-diabetic
agent metformin may have signiﬁcant anti-tumoractivity. This is an economical and effective anti-diabetic
agent used by more than 120 million patients world-
wide and is well-tolerated by non-diabetics too. Met-
formin is believed to mediate anti-tumor action through
blockade of mitochondrial OxPhos complex I and in-
duction of a stage of mild metabolic stress that activates
the AMP-activated kinase pathway (AMPK), an enzyme
with tumor suppressor activity.
We showed that AMPK is a sensor of both metabolic
and genotoxic stress that mediates cell cycle arrest and
tumor suppression. Our pre-clinical translational and
retrospective clinical studies suggested that targeting
metabolism in NSCLC with metformin enhances NSCLC
radio-sensitivity and could improve outcomes in locally
advanced NSCLC.
NRG-LU001 (NCT02186847) is an NCI-CTEP funded
trial that opened to accrual in August 2014. It is designed
to examine speciﬁcally whether metformin could radio-
chemo-sensitize NSCLC in locally advanced stage III (A
and B) patients. Its primary outcome is 1 year progres-
sion free survival (PFS) and secondary outcomes
include: overall survival (OAS); time to local-regional
progression (LRP); time to distant metastasis (DM);
Chemo-RT toxicity; biospecimen collection for biomarker
analysis. This will include: circulating serum and blood
cell biomarkers of metformin activity and tumor
response and tumor biomarkers such as tumor histology,
TP53, LKB1 and K-Ras mutation status.
NRG-LU001 target accrual is 168 patients with 1:1
randomization to either chemo-radiotherapy (CRT) alone
vs CRT and metformin of 2000mg daily given only during
cytotoxic therapy. This includes concurrent CRT for 6
weeks followed by 6 weeks of consolidation chemo-
therapy treatment. Chemotherapy, in both the concurrent
and the consolidate phase of this study is the carboplatin-
paclitaxel doublet, while patients receive standard chest
RT of 60Gy in 30 fractions. Sample size calculations are
based on observed 1-year PFS of 50% (RTOG-0617 data)
and an expected improvement of 15% with metformin.
With 152 analyzable patients this study will have 85%
power to detect this improvement. The number is
increased to 168 to allow 10% rate of ineligibility.
LU001 is currently open in 52 centers across North
America. This is one of the ﬁrst clinical trials investi-
gating the potential of metabolism modulating agents to
enhance chemo-RT responses in locally advanced
NSCLC. It is expected to provide initial efﬁcacy results
for this agent and assist in the investigation and
development of circulating and tumor biomarkers of
metformin action and sensitivity. If positive this study
will allow us to design rationally future phase III
studies to examine deﬁnitively the role of metformin in
this setting.
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Lung tumor metabolism is severely altered involving
enhanced levels of glucose uptake, glycolysis, lipogenesis
and protein synthesis. These events are essential for the
support of enhanced energy demands and increased
need for ribonucleotides, proteins and membrane
biogenesis that are required for rapid proliferation.
Combined treatment with cytotoxic therapy and
metabolism modulating agents may improve outcomes
in NSCLC. We observed that radiotherapy (RT) alone
activates the metabolic stress sensor AMP-activated ki-
nase (AMPK) within an Ataxia Telengiectasia Mutated
(ATM) – AMPK – p53/p21cip1 pathway to mediate the
RT-induced G2-M checkpoint and cytotoxicity. Further,
inhibition of biosynthetic pathways and energy produc-
tion through blockade of OxPhos inhibits tumor growth.
In human NSCLC cells and xenografts, we combined RT
with the anti-diabetic agent metformin, which blocks
OxPhos complex I, and showed that metformin activates
the ATM-AMPK-p53/p21cip1 axis and inhibits the Akt-
mTOR-4EBP1 pathway, tumor growth and angiogenesis
and induces apoptosis and radio-sensitization.
Based on these observations and supporting retrospec-
tive clinical evidence from locally advanced lung cancer
patients treated with Chemo-RT, we launched phase II
studies combiningmetforminwith chemo-RT. NRG-LU001
(NCT02186847) and OCOG ALMERA (NCT02186847)
are on-going randomized phase II studies investigating
whether targeting metabolism with metformin can
improve progression free survival in stage III NSCLC.
In recent studies we observed that combined treat-
ment with metabolism modulating agents can enhance
anti-tumor activity in NSCLC. Combined treatment with
Metformin and Salicylate, which activate AMPK through
different mechanisms, mediated increased inhibition of
clonogenic survival in part through AMPK and sup-
pression of de-novo lipogenesis. Further, in earlier
studies we showed that blockade of the cholesterol
synthesis pathway with lovastatin (HMG-CoA reductase
inhibitor) mediated activation of AMPK, suppression ofthe Akt-PI3k pathways and radio-sensitization of
NSCLC.
In current studies we observe that lovastatin also ac-
tivates the ATM-AMPK-p53 axis, inhibit the Akt-mTOR
pathway and mediate tumor suppression in an AMPK-
dependent manner through suppression of de novo
lipogenesis along both the mevalonate and the fatty acid
synthesis pathways. Further, in retrospective clinical
studies we ﬁnd that in locally advanced NSCLC patients
treated with Chemo-RT, statin treatment is associated
with increased survival.
These observations suggest that targeting tumor
metabolism is promising in NSCLC to improve outcomes
of standard cytotoxic therapy. Completion of on-going
trials with metformin will provide the ﬁrst prospective
evidence on this concept. We plan to investigate com-
binations of well-tolerated metabolism modulating
agents that show promising pre-clinical activity in future
rolling phase II studies.
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LA-NSCLC is frequently unresectable and is treated with
concurrent chemo-radiotherapy (CRT), which is fairly
toxic and provides poor disease control and overall
survival. There is an urgent need to develop sensitizers
to cytotoxic therapy that could improve the therapeutic
ratio in this disease.
Preclinical studies from our group and others demon-
strated that the biguanide metformin has activity in lung
cancer and sensitizes lung cancer cells and tumors to
radiotherapy and chemotherapy. Metformin is known to
induce in cells a state of mild metabolic stress through
blockade of the mitochondria OxPhos complex I. We
showed that metformin alone triggers activation of the
ATM-AMP-kinase-p53/p21cip1 pathway, inhibition of the
radio-resistance Akt-mTOR pathway, radio-sensitizes
NSCLC, enhances apoptosis and inhibits angiogenesis.
Metformin is an economical and effective anti-diabetic
agent that is well-tolerated by non-diabetics too. Based
on our pre-clinical results and additional supporting
retrospective data from stage III NSCLC patients treated
with chemo-radiotherapy, we launched a phase II clinical
trial in locally advanced NSCLC combining metformin
with concurrent CRT.
